Eli Health, a women's health company on a mission to improve lifelong health through continuous hormone monitoring, has closed its US $3.6 million seed round. The funding will be primarily used to improve women's health with saliva-based continuous hormone-monitoring technology.
This round was led by Muse Capital, a venture capital firm that focuses on underserved markets such as women's health. The round also included participation from San Francisco-based firms RH Capital and Cake Ventures, diverse group of healthcare and technology investors.
A Fasken team led by Adam Saskin, Jonathan Raizenne and Tristan Lalumière-Roberge advised Eli Health in connection with this financing.
Jurisdiction
- Québec
